EUCTR2016-001835-11-AT进行中（未招募）1 期
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)Revised Lung Master Protocol: 07 (revprot07)Incorporates Administrative Letter: 01(Sub-protocol A Revised version 03 dated 16-Feb-2017 + Sub-protocol B Revised version 01 dated 12-Oct-2018) - FRACTION-Lung
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 295
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For the master Protocol :
- •-Advanced Non Small Cell Lung Cancer (NSCLC)
- •-ECOG Performance status of = 1
- •-Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
- •-Must have at least 1 lesion with measurable disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 302
排除标准
- •For the master Protocol :
- •-Subjects with certain mutations must have been treated with a targeted therapy prior to enrollment
- •-Must not have suspected or known central nervous system metastases unless adequately treated
- •-Subjects who need daily oxygen therapy
- •-People with autoimmune disease
研究者
相似试验
进行中（未招募）
不适用
This is a trial for women with metastatic breast cancer that test positive for a biological protein called Her 2 and a biological enzyme called Topoisomerase II alpha.Patients will receive Epirubicin and Lapatinib.Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive.MedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005002-30-IEICORG-the All Ireland co-operative Oncology Research group46
进行中（未招募）
1 期
Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell MalignanciesPart 1: De novo Diffuse large B-cell lymphoma (DLBCL), Transformed DLBCL and Richter syndrome (RS). Part 2: De novo Germinal center B-cell (GCB) DLBCL and De novo non-GCB DLBCLMedDRA version: 20.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10058728 Term: Richter's syndrome System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003736-21-GBAcerta Pharma BV71
进行中（未招募）
1 期
A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCCMetastatic Renal Cell Carcinoma (RCC)MedDRA version: 8.1Level: HLTClassification code 10038408Term: Renal cell carcinomasEUCTR2006-004822-97-GBThe Royal Marsden NHSF Trust51
进行中（未招募）
2 期
ONO-7702/7703-03:NO-7702/ONO-7703 Phase2 StudyRadically unresectable BRAF V600-mutant thyroid cancerJPRN-jRCT2011200018Hirashima Yoshinori19
进行中（未招募）
1 期
A phase II study evaluating the use of concurrent cetuximab, irinotecan, oxaliplatin and UFT in the first line treatment of patients with metastatic colorectal cancer - e-SCOUTAdvanced, inoperable or metastatic colorectal cancer.EUCTR2007-002053-24-GBThe Christie NHS Foundation Trust